Previous close | 0.6100 |
Open | 0.6100 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.6100 - 0.6100 |
52-week range | 0.4500 - 0.9500 |
Volume | |
Avg. volume | 195 |
Market cap | 6.729M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2500 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Beverly Hills, California., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTC PINK: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a paying Consultancy Agreement with Orocidin A/S in Denmark. Orocidin A/S (“Orocidin”) is a clinical-stage biopharmaceutical company focused on the discovery, deve
Las Vegas, Nevada., June 21, 2023 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTC PINK: NORD) (“Nordicus” or the “Company”), a financial consulting company, specializing in providing Nordic and U.S. companies with the best possible conditions to establish themselves on the U.S. market, today announced it entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which a private seller sold to the Company 5,000,000 restricted shares of common stock of Mag Mile Capital, Inc.
Las Vegas, Nevada., May 22, 2023 (GLOBE NEWSWIRE) -- EKIMAS Corporation (OTC PINK: NORD) (“EKIMAS” or the “Company”), a financial consulting company specializing in providing Nordic companies with the best possible conditions to establish themselves on the U.S. market, today announced that its common stock began trading under the symbol ‘NORD’ on May 17, 2023 and changed its name to Nordicus Partners Corporation. The new ticker symbol aligns with the Company’s rebranding to Nordicus. No action b